Hester Bange
Leiden, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Identification of drug repurposing candidates for the treatment of polycystic kidney disease.
Journal: British journal of pharmacology
Published: August 15, 2025
Targeted analysis of salicylate binding partners in renal epithelial cells reveals major AMPK dependency.
Journal: Biochimica et biophysica acta. Molecular cell research
Published: March 03, 2025
A Patient-Derived 3D Cyst Model of Polycystic Kidney Disease That Mimics Disease Development and Responds to Repurposing Candidates.
Journal: Clinical and translational science
Published: October 30, 2024
Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease.
Journal: Frontiers in pharmacology
Published: March 08, 2024
A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease.
Journal: Kidney international
Published: June 16, 2022
Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective.
Journal: Scientific reports
Published: October 28, 2019
Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles.
Journal: EBioMedicine
Published: September 13, 2019
In vitro 3D phenotypic drug screen identifies celastrol as an effective in vivo inhibitor of polycystic kidney disease.
Journal: Journal of molecular cell biology
Published: June 17, 2018
High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease.
Journal: SLAS discovery : advancing life sciences R & D
Published: June 24, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026